

Influence of major *BCR-ABL1* transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Multivariate analysis to identify factors predictive of MR^{4.0}

<i>Univariate analysis</i>	OR	[95% CI OR]	MMR at 12 months N (%)	No MMR at 12 months N (%)	<i>p</i> =
Male					
Yes	0.49	[0.24–1.00]	31 (45.6)	36 (63.2)	.05
No			37 (54.6)	21 (36.8)	
Splenomegaly					
Yes	0.21	[0.08–0.57]	6 (8.8)	18 (31.6)	.002
No			62 (91.2)	39 (68.4)	
WBC count (> 150 × 10³/μL)					
Yes	0.30	[0.14–0.64]	18 (26.5)	31 (54.4)	.002
No			50 (73.5)	26 (45.6)	
PLT count (> 300 × 10³/μL)					
Yes	2.68	[1.27–5.67]	50 (73.5)	29 (50.9)	.009
No			18 (26.5)	28 (49.1)	
Hemoglobin (> 120 g/L)					
Yes	2.44	[1.17–5.08]	36 (52.9)	18 (31.6)	.02
No			31 (47.1)	39 (68.4)	
High ELTS score					
Yes	0.30	[0.10–0.90]	5 (7.4)	12 (21.1)	.03
No			63 (92.6)	45 (78.9)	
High Sokal score					
Yes	0.87	[0.38–2.00]	29 (23.2)	14 (24.6)	.74
No			96 (76.8)	43 (75.4)	
ACA or variant translocation					
Yes	2.01	[0.71–5.68]	13 (19.4)	6 (10.7)	.18
No			54 (80.6)	50 (89.3)	
Transcript e14a2, alone or co-expressed					
Yes	2.17	[1.05–4.48]	46 (67.6)	28 (49.1)	.04
No			22 (32.4)	29 (50.9)	
Multivariate analysis	OR	[95% CI OR]			<i>p</i> =
Male	0.74	[0.31–1.81]			.51
Splenomegaly	0.27	[0.07–1.06]			.06
WBC count	0.58	[0.22–1.54]			.27
Platelets	2.58	[1.03–6.47]			.04
Hemoglobin	1.84	[0.76–4.47]			.18
ACA or variant translocation	3.04	[0.91–10.10]			.07
ELTS score	1.81	[0.38–8.53]			.45
e14a2	2.15	[0.93–4.97]			.07

Abbreviations: OR, odds ratio; ACA, additional chromosome abnormalities in Ph⁺ cells; EUTOS, European Treatment and Outcome Study; ELTS; PLT, platelets; WBC, white blood cells. Variables with *p* values inferior to 0.20 in univariate analysis were included in the multivariate model.